In another example, Beysen et al. explored the therapeutic potential of drug candidate FT‐4101, a fatty acid synthase (FASN) inhibitor, on hepatic steatosis in patients with NAFLD. This evidence concerns the gene FASN and metabolic dysfunction-associated steatotic liver disease.